USPTO serial 87604011
NITYR
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 2, 2019
- Examiner
- BELENKER, ESTHER
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 705 means a Madrid-based U.S. registration has accepted Section 71 maintenance and Section 15 incontestability. The U.S. extension is active with strengthened rights. Track next renewal deadlines in TSDR and WIPO records.
Need help with NITYR?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
J. Scott Evans
J. Scott Evans Stobbs214 W. TremontSuite 303Charlotte, NC 28203Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | (Based on 44(e)) Pharmaceutical agents for the treatment of [ disorders of the metabolism and digestive system, pharmaceutical agents for the treatment of ] tyrosinemia [ and hypertyrosinemia, all ] in the form of [ liquids, solutions, suspensions, syrups, drops, capsules, ] tablets [ , caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; parts and fittings for all of the aforementioned goods.; pharmaceutical preparations for the treatment of disorders of the metabolism and digestive system, pharmaceutical preparations for the treatment of tyrosinemia and hypertyrosinemia, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; pharmaceuticals for the treatment of disorders of the metabolism and digestive system, pharmaceuticals for the treatment of tyrosinemia and hypertyrosinemia all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; Veterinary preparations for treatment of intestinal bacteria; veterinary preparations, namely, antioxidants; veterinary preparations namely, pain relief medications; veterinary preparations for treatment of chronic illnesses; veterinary preparations for treatment of viral diseases; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use; dietary supplements for humans and animals supplements for the treatment of disorders of the metabolism and digestive system, supplements for the treatment of tyrosinemia and hypertyrosinemia, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; (Based on Use in Commerce) food for babies; medical dressings; plasters for medical purposes; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides; biological preparations for the treatment of disorders of the metabolism and digestive system, biological preparations for the treatment of tyrosinemia and hypertyrosinemia, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; chemical preparations for the treatment of disorders of the metabolism and digestive system, chemical preparations for the treatment of tyrosinemia and hypertyrosinemia, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals, drug delivery agents for use in pharmaceuticals, drugs and medicines for the treatment of disorders of the metabolism and digestive system, drug delivery agents for use in pharmaceuticals, drugs and medicines for the treatment of tyrosinemia and hypertyrosinemia, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; drugs for the treatment of rare diseases, in particular for the treatment of disorders of the metabolism and digestive system, drugs for the treatment of rare diseases, in particular for the treatment of tyrosinemia and hypertyrosinemia, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; enzyme preparations for medical purposes, enzyme preparations for the treatment of disorders of the metabolism and digestive system, enzyme preparations for the treatment of tyrosinemia and hypertyrosinemia, medical enzyme preparations in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; enzyme preparations for veterinary purposes; medical preparations for the treatment of disorders of the metabolism and digestive systems, medical preparations for the treatment of tyrosinemia and hypertyrosinemia, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; medicines for the treatment of disorders of the metabolism and digestive system, medicines for the treatment of tyrosinemia and hypertyrosinemia, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches ] | ACTIVE | Aug 1, 2017 |
| 035 | [ (Based on 44(e)) Advertising services; marketing services; business management; business administration services; providing office functions; advertising and marketing relating to medical and pharmaceutical goods and services; advertising and marketing relating to pharmaceuticals, medicines and supplements for the treatment of disorders of the metabolism and digestive system; advertising and marketing relating to pharmaceuticals, medicines and supplements for the treatment of tyrosinemia and hypertyrosinemia; advertising and marketing relating to pharmaceuticals, medicines and supplements for the treatment of rare diseases; business information in the field of pharmaceuticals, medicines and supplements for the treatment of disorders of the metabolism and digestive system; business information in the field of pharmaceuticals, medicines and supplements for the treatment of tyrosinemia and hypertyrosinemia; business information in the field of pharmaceuticals, medicines and supplements for the treatment of rare diseases; business information in the field of pharmaceuticals, medicines and supplements; providing business information; on-line wholesale store services featuring pharmaceuticals, medicines and supplements for the treatment of rare diseases; on-line wholesale store services featuring medical and pharmaceutical goods and services; on-line wholesale store services featuring pharmaceuticals, medicines and supplements for the treatment of disorders of the metabolism and digestive system; on-line wholesale store services featuring pharmaceuticals, medicines and supplements for the treatment of tyrosinemia and hypertyrosinemia; promoting the goods and services of others via the internet in the medical and pharmaceutical industries; promoting the goods and services of others via the internet; retail pharmacy and drugstore services; retail store services featuring pharmaceuticals, medicines and supplements for the treatment of disorders of the metabolism and digestive system; retail store services featuring pharmaceuticals, medicines and supplements for the treatment of tyrosinemia and hypertyrosinemia; retail store services featuring pharmaceuticals, medicines and supplements for the treatment of rare diseases; retail store services featuring pharmaceuticals, medicines and supplements in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches ] | SECTION 8 - CANCELLED | — |
| 044 | [ (Based on 44(e)) Medical services; veterinary services; hygienic and beauty care for human beings or animals; horticulture services; dispensing of pharmaceuticals, medicines and supplements for the treatment of disorders of the metabolism and digestive system; dispensing of pharmaceuticals, medicines and supplements for the treatment of rare diseases; dispensing of pharmaceuticals, medicines and supplements for the treatment of tyrosinemia and hypertyrosinemia; dispensing of pharmaceuticals, medicines and supplements; dispensing of pharmaceuticals, medicines and supplements in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; genetic testing in relation to disorders of the metabolism and digestive system; genetic testing in relation to rare diseases; genetic testing in relation to tyrosinemia and hypertyrosinemia; genetic testing for medical purposes; providing healthcare and medical information in relation to disorders of the metabolism and digestive system; providing healthcare and medical information in relation to rare diseases; providing healthcare and medical information in relation to tyrosinemia and hypertyrosinemia; providing medical product information and advisory services in relation to the treatment of disorders of the metabolism and digestive system; providing medical product information and advisory services in relation to the treatment of rare diseases; providing medical product information and advisory services in relation to the treatment of tyrosinemia and hypertyrosinemia; medical, pharmacological and pharmaceutical testing services for diagnostic and treatment purposes; medical, pharmacological and pharmaceutical testing services in relation to disorders of the metabolism and digestive system; medical, pharmacological and pharmaceutical testing services in relation to rare diseases; medical, pharmacological and pharmaceutical testing services in relation to tyrosinemia and hypertyrosinemia; providing pharmaceutical information and advisory services in relation to the treatment of disorders of the metabolism and digestive system; providing pharmaceutical information and advisory services in relation to the treatment of rare diseases; providing pharmaceutical information and advisory services in relation to the treatment of tyrosinemia and hypertyrosinemia; providing information in relation to medical, pharmacological and pharmaceutical products for the treatment of disorders of the metabolism and digestive system; providing information in relation to medical, pharmacological and pharmaceutical products for the treatment of rare diseases; providing information in relation to medical, pharmacological and pharmaceutical products for the treatment of tyrosinemia and hypertyrosinemia; providing news and information in the field of disorders of the metabolism and digestive system; providing news and information in the field of medicine in relation to tyrosinemia and hypertyrosinemia; providing news and information in the field of medicine; providing news and information in the field of rare diseases ] | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Cycle Pharmaceuticals Ltd.
- Other trademarks owned by Cycle Pharmaceuticals Ltd.
- Other trademarks owned by Cycle Pharmaceuticals Ltd.
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 044
- Similar marks named NITYR
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 10, 2026 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Sep 10, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 10, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 10, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 16, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 16, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 16, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 21, 2025 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| May 21, 2025 | C15P | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| May 15, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 16, 2025 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Jan 23, 2025 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Apr 3, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 3, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 3, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 2, 2024 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Mar 15, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 15, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 15, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 28, 2020 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| May 20, 2019 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 2, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 27, 2019 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Feb 26, 2019 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Feb 26, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 26, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 25, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 15, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 15, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 15, 2019 | CNRT | SU - NON-FINAL ACTION - WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 14, 2019 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Feb 14, 2019 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 23, 2019 | IUAF | USE AMENDMENT FILED | — |
| Jan 23, 2019 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jan 17, 2019 | NOAC | CORRECTED NOA E-MAILED | — |
| Oct 30, 2018 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 4, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 4, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 15, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 10, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 1, 2018 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Jul 27, 2018 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Jul 24, 2018 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Jul 13, 2018 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Jul 12, 2018 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Jun 29, 2018 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Jun 27, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 27, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 27, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 27, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 27, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 20, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 20, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 11, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 1, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 1, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 1, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 11, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 11, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 5, 2018 | ALIE | ASSIGNED TO LIE | — |
| Mar 22, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 19, 2017 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 14, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 14, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 14, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 14, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 15, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 14, 2017 | NWAP | NEW APPLICATION ENTERED | — |